Medicamen Biotech liquidity ratios

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

4.20×	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
2.54×	2.54×	2.11×	1.75×	1.98×
1.75×	1.75×	1.31×	1.10×	1.43×
31.3	31.3	3.8	14.8	20.8
136	136	86.4	68.6	80.8

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

MEDICAMEQ₹251.90

Medicamen Biotech Limited

· Pharma & Health

₹ CrorePeersMEDICO AAREYDRUGS NECLIFE HALEOSLABS ALBERTDAVD NATCAPSUQ VALIANTLAB BALPHARMAMcap ₹342 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Altman Z-Score (Other Equity as RE)	—	—	—	—	4.20
Current Ratio	1.98	1.75	2.11	2.54	2.54
Quick Ratio	1.43	1.10	1.31	1.75	1.75
Cash, Equiv & ST Investments	20.8	14.8	3.8	31.3	31.3
Working Capital	80.8	68.6	86.4	135.8	135.8

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.